M/S T.c.healthcare P. Ltd. v. Union of India

Court

Supreme Court of India

Decided

15 November 2019

Case no.

C.A. No.-004687-004687 - 2010

Bench

Rohinton Fali Nariman, S. Ravindra Bhat

Author

S. Ravindra Bhat

Facts

The appellants, T.C. Healthcare and Modi Mundipharma, were small-scale manufacturers of drugs and were exempt from price fixation under the DPCO due to their status as small-scale units. The notifications in question were issued on July 11, 2006, and April 30, 2009, which set ceiling prices for formulations containing Frusemide and Potassium. The appellants contended that the price fixation was arbitrary and lacked consideration of manufacturing costs and efficiency. They filed writ petitions in the Allahabad High Court after receiving demand notices related to the price ceilings.

Arguments

Petitioner Arguments

The appellants argued that

• The price fixation was arbitrary and resulted from a lack of proper consideration by the Central Government.
• The notifications did not take into account the cost and efficiency of major manufacturers.
• The price fixation was ultra vires Para 7 of the DPCO, as there were no established price norms for formulations using sustained release technology.
• The respondents failed to provide necessary data regarding costs and efficiency.

The court addressed these arguments by emphasizing that the appellants did not provide sufficient evidence to support their claims of arbitrariness or lack of consideration.

Respondent Arguments

The respondents, representing the Central Government, contended that

• The price fixation was based on comprehensive data and analysis.
• The notifications were within the scope of the DPCO and adhered to the regulatory framework.
• The appellants did not substantiate their claims regarding the inefficacy of the price fixation process.

The court found the respondents' arguments compelling, noting that the appellants failed to demonstrate any procedural flaws or lack of data in the price fixation process.

Precedents considered

The judgment did not explicitly cite prior case law but relied on the principles established under the DPCO. The court's reasoning was grounded in the regulatory framework governing drug pricing, emphasizing the government's authority to regulate prices for public health considerations.

Legal principles

The court considered several legal principles, including

• The authority of the Central Government to fix drug prices under the DPCO.
• The requirement for manufacturers to provide data when challenging price notifications.
• The principle of reasonableness in administrative actions, which necessitates that decisions are made based on relevant considerations.

Decision and reasoning

Rationale

The court reasoned that the appellants did not provide adequate evidence to support their claims of arbitrary action by the government. It highlighted that the government had a duty to ensure affordable healthcare and that the price fixation was a legitimate exercise of its regulatory powers. The court also noted that the appellants' failure to substantiate their claims weakened their position.

Outcome

The Supreme Court dismissed the appeals, affirming the High Court's decision. The court did not provide specific instructions for an appeal process, as the judgment was final regarding the issues raised.

Conclusion

This judgment reinforces the government's authority to regulate drug prices in the interest of public health. It underscores the importance of providing substantial evidence when challenging administrative actions and clarifies the standards for evaluating the reasonableness of such actions.

Read the full judgment on the Supreme Court website (PDF)